The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

​ Conditions: Advanced Kidney Cancer

Interventions: Drug: Nivolumab & Ipilimumab; Drug: Nivolumab + Ipilimumab

Sponsors: Guliz Ozgun; British Columbia Cancer Agency

Not yet recruiting Conditions: Advanced Kidney Cancer
Interventions: Drug: Nivolumab & Ipilimumab; Drug: Nivolumab + Ipilimumab
Sponsors: Guliz Ozgun; British Columbia Cancer Agency
Not yet recruiting